Patients Who May Benefit from Medicinal Cannabis: A Clinical Perspective

The evidence base for medicinal cannabis continues to grow. While research is still maturing in many areas, there are patient populations where clinical outcomes and published data provide meaningful support for its use. Here, we outline those profiles in plain terms.

Chronic Pain Patients

This is the most common indication in Australia. Patients who have lived with persistent pain for three months or more — including those with neuropathic pain, musculoskeletal pain, and pain related to injury or surgery — represent the majority of medicinal cannabis prescriptions. For many, it offers an alternative or adjunct to opioid-based management, which carries significant risks including dependence.

Patients with Anxiety and PTSD

CBD-dominant products have shown promise in reducing anxiety symptoms in both clinical and observational studies. Patients with treatment-resistant anxiety disorders or PTSD, particularly those who have not responded adequately to first-line pharmacotherapy, may benefit from a carefully managed cannabis protocol. Doctors will screen for personal or family history of psychotic illness, which is a relative contraindication.

People with Insomnia

Sleep disturbances are among the most commonly reported indications. THC-containing products may help reduce sleep onset time and increase total sleep duration. CBD alone may address anxiety-driven insomnia. The right approach depends on whether the insomnia is primary or secondary to another condition.

Patients with Neurological Conditions

Multiple sclerosis patients experiencing spasticity, and people with treatment-resistant epilepsy — particularly children with Dravet syndrome or Lennox-Gastaut syndrome — represent areas where the evidence is most established. Epidiolex, a pharmaceutical-grade CBD product, is TGA-registered for specific paediatric epilepsy syndromes.

Cancer Patients and Palliative Care

Patients experiencing chemotherapy-induced nausea and vomiting, cancer-related pain, and appetite loss may benefit from medicinal cannabis as part of a broader palliative or supportive care plan. It does not replace standard cancer treatment — but as an adjunct, it can meaningfully improve quality of life.

Older Patients

Older Australians are the fastest-growing demographic accessing medicinal cannabis. For patients managing multiple chronic conditions on complex medication regimens, a CBD-dominant approach may provide symptom relief with a manageable side-effect profile. Careful prescribing and regular review are important in this group.